



3Q 2021 Financial results

3Q 2021

Worldwide sales
\$13.2 billion

GAAP EPS
\$1.80

Non-GAAP EPS
\$1.75

2021 Continuing operations financial outlook

Expects full-year 2021 sales growth of 14% to 15%; raises and narrows estimated full-year 2021 revenue range to be between \$47.4 billion and \$47.9 billion, including a positive impact from foreign exchange of approximately 1.5%

Raises and narrows full-year 2021 GAAP EPS to be between \$4.71 and \$4.76; raises and narrows full-year 2021 Non-GAAP EPS to be between \$5.65 and \$5.70, including a positive impact from foreign exchange of approximately 2%

Key growth drivers

Oncology

KEYTRUDA®
(pembrolizumab) injection 100 mg

Higher sales and continued uptake

 +  | **Lynparza®**
olaparib tablets 150 mg

 +  | **LENVIMA®**
(lenvatinib) capsules 10 mg and 4 mg

Vaccines


GARDASIL®
[Human Papillomavirus Quadrivalent
(Types 6, 11, 16, and 18) Vaccine, Recombinant]

+


GARDASIL® 9
[Human Papillomavirus
9-valent Vaccine, Recombinant]

Growth driven by higher demand in China, as well as increased supply and ability to reallocate

Hospital Acute Care

bridion®
(sugammadex) injection 100 mg/mL*

Higher demand globally and pandemic recovery

Animal Health

 **MERCK**
Animal Health

Higher global demand in companion animal and livestock products, including Animal Health Intelligence products



“Merck delivered another strong quarter with positive momentum across our business and meaningful progress across our pipeline. Our teams continued to excel as we focus on evolving our operations, while driving innovations in our labs that exemplify the best of Merck science.

We achieved notable clinical milestones in the key areas of oncology and COVID-19, including positive Phase 3 results for molnupiravir. We recently announced our proposed acquisition of Acceleron, which will strengthen our cardiovascular portfolio with complementary, cutting-edge science and an exciting late-stage candidate.

Looking ahead, we remain focused on building more momentum, delivering on our mission of saving and improving lives and continuing to expand our portfolio and pipeline for long-term success and sustainable value creation.”

Rob Davis
CEO and President

Creating long-term value for patients, employees and shareholders

See investors.merck.com for Merck's full 3Q earnings release issued October 28, 2021, the associated webcast presentation, forward-looking statement, definitions of non-GAAP measures and reconciliations to the most closely related GAAP measure.